Pacira Biosciences, Inc. (PCRX) — 8-K Filings

8-K Filings (19)

• Pacira BioSciences Files 8-K on Financials — Aug 5, 2025 Risk: low
  On August 5, 2025, Pacira BioSciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statement
• Pacira BioSciences Files 8-K on Exit Costs — Jul 10, 2025 Risk: medium
  On July 9, 2025, Pacira BioSciences, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included Regulation FD
• Pacira BioSciences Enters New Agreements, Terminates Others — Jul 7, 2025 Risk: medium
  On July 3, 2025, Pacira BioSciences, Inc. entered into a material definitive agreement and simultaneously terminated another. The company also created a direct
• Pacira BioSciences Reports Director/Officer Changes & More — Jun 13, 2025 Risk: medium
  Pacira BioSciences, Inc. filed an 8-K on June 13, 2025, reporting on events that occurred on June 10, 2025. The filing covers the departure of directors or cert
• Pacira BioSciences Acquires Pain Management Assets — Apr 22, 2025 Risk: medium
  Pacira BioSciences, Inc. announced on April 17, 2025, that it has entered into a definitive agreement to acquire the assets of a privately held company for $100
• Pacira BioSciences Files 8-K: Material Agreement & Financials — Apr 7, 2025 Risk: medium
  On April 7, 2025, Pacira BioSciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and
• Pacira BioSciences Files 8-K for Bylaws and Exhibits — Mar 14, 2025 Risk: low
  Pacira BioSciences, Inc. filed an 8-K on March 14, 2025, reporting events as of March 12, 2025. The filing primarily concerns amendments to its articles of inco
• Pacira BioSciences Files 8-K on Financials — Feb 27, 2025 Risk: low
  Pacira BioSciences, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Pacira BioSciences Appoints New CEO, David Stack — Jan 30, 2025 Risk: medium
  Pacira BioSciences, Inc. announced on January 28, 2025, the appointment of Dr. David M. Stack as Chief Executive Officer, effective immediately. Dr. Stack, who
• Pacira BioSciences Announces CFO Departure, New CFO & Directors — Jan 21, 2025 Risk: medium
  Pacira BioSciences, Inc. announced on January 16, 2025, the departure of its Chief Financial Officer, Hubert "Hub" Davis. The company also announced the appoint
• Pacira BioSciences Files 8-K on Financials — Jan 10, 2025 Risk: low
  Pacira BioSciences, Inc. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Pacira BioSciences Appoints New CMO, Director — Oct 21, 2024 Risk: low
  Pacira BioSciences, Inc. announced on October 16, 2024, the appointment of Dr. Michael J. Zinner as Chief Medical Officer and the election of Ms. Amy E. Paul to
• Pacira BioSciences Reports Director/Officer Changes — Sep 27, 2024 Risk: medium
  Pacira BioSciences, Inc. filed an 8-K on September 27, 2024, reporting changes effective September 26, 2024. The filing pertains to the departure of directors o
• Pacira BioSciences to be Acquired for $3.3 Billion — Sep 9, 2024 Risk: medium
  Pacira BioSciences, Inc. announced on September 3, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of 22NW, LP. The transac
• Pacira BioSciences Files 8-K — Aug 9, 2024 Risk: low
  Pacira BioSciences, Inc. (PCRX) filed an 8-K on August 9, 2024, reporting other events and financial statements. The company, formerly known as Pacira Pharmaceu
• Pacira BioSciences Appoints New CEO, Dr. David Stack — Jun 13, 2024 Risk: medium
  Pacira BioSciences, Inc. announced on June 11, 2024, the appointment of Dr. David M. Stack as Chief Executive Officer and a member of the Board of Directors, ef
• Pacira BioSciences Files 8-K on Financial Obligations and Equity Sales — May 14, 2024 Risk: medium
  On May 9, 2024, Pacira BioSciences, Inc. entered into a Material Definitive Agreement related to a direct financial obligation. The company also reported on the
• Pacira BioSciences Enters Material Definitive Agreement — May 8, 2024 Risk: medium
  On May 8, 2024, Pacira BioSciences, Inc. entered into a Material Definitive Agreement related to financial obligations. The company, formerly known as Pacira Ph
• Pacira BioSciences Files 8-K on Operations & Financial Condition — Jan 4, 2024
  Pacira BioSciences, Inc. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition. This filing, under Items 2.02 and 9.01

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX